Human Verification
In order to continue, you need to verify that you're…
The company recently announced that two wholly owned, precision oncology development candidates, EXS74539 ('539), an LSD1 inhibitor and EXS73565 ('565), a MALT1 protease inhibitor have been precision designed. Exscientia says this will improve the potential for patient benefit and solve complex design issues that could limit the probability of success of other compounds in the development.…
UK-based company that uses artificial intelligence (AI) in drug
discovery Exscientia (Nasdaq: EXAI) saw its shares edge up 2.8%
to $6.86 in morning trading today, despite announcing that US
pharma major Bristol Myers Squibb (NYSE: BMY) would not be taking
up an option under an agreement with Celgene.
As…
Viz.ai is already an old hand at putting its disease-spotting artificial intelligence algorithms through the FDA review process, having secured the agency’s sign-off for seven of the AI tools to da | Viz.ai is already an old hand at putting its disease-spotting artificial intelligence algorithms through the FDA review process, having secured the agency’s sign-off…
Viz.ai announced today that it entered into a multi-year agreement with Bristol Myers Squibb (NYSE:BMY) for detecting hypertrophic cardiomyopathy.
The partnership seeks to deploy an AI algorithm and the Viz HCM provider workflow software. This can help identify and triage patients who may require further evaluation for the detection of hypertrophic cardiomyopathy.
San Francisco-based Viz.ai submitted…
Viz.ai signed a multi-year agreement with Bristol Myers Squibb (BMY) to deploy an artificial intelligence ((AI)) algorithm and provider workflow software (Viz HCM) to identify patients...
Viz.ai, a leader in AI-powered disease detection and care coordination, today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY),
Credit: Yuuji/Getty Images
AI pathology specialist PathAI has announced a multi-year expanded collaboration agreement with Bristol Myers Squibb. The initial work within this extended agreement will focus on key translational research in oncology, fibrosis, and immunology, with an overall goal to forward these into clinical trials. PathAI…
PathAI has expanded a multi-year partnership agreement with Bristol Myers Squibb (BMS) to leverage artificial intelligence (AI)-powered pathology in translational research and clinical trials.
In the initial stage, the deal will focus on key translational research in oncology, fibrosis and immunology areas to advance the work into clinical development.
Under the alliance, the companies will…
PathAI, a company that centers on artificial intelligence (AI) powered pathology, has announced a multi-year, expanded collaborative agreement with pharmaceutical company Bristol Myers Squibb (BMS). According to the collaborators, the work initially will focus on translational research in the areas of oncology, fibrosis, and immunology; the overall goal reportedly is to continue transitioning the work…